> For the complete documentation index, see [llms.txt](https://www.parapathology.com/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.parapathology.com/clippings/etv4-ets-variant-transcription-factor-4.md).

# ETV4: ETS Variant Transcription Factor 4

Comprehensive diagnostic pathology digest on ETV4 (ETS Variant Transcription Factor 4 / PEA3 / E1AF) immunohistochemistry. Focuses on its role as a surrogate nuclear marker for CIC-rearranged round ce

Diagnostic immunohistochemistry profile, surrogate molecular diagnostic mechanisms, and differential diagnostic panels for **ETV4 (ETS Variant Transcription Factor 4 / PEA3 / E1AF)** based on [PathologyOutlines: ETV4](https://www.pathologyoutlines.com/topic/stainsetv4.html) and soft tissue pathology consensus guidelines.

***

## Executive Overview & Molecular Biology

| Feature                             | Specification                                                                                                                                                                           |
| ----------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **Gene Symbol**                     | *ETV4* (HGNC: 3493; Entrez: 2118; Ensembl: ENSG00000175832)                                                                                                                             |
| **Chromosomal Locus**               | Chromosome 17q21.31                                                                                                                                                                     |
| **Alternative Names**               | PEA3 (Polyomavirus Enhancer Activator 3), E1AF (E1A-F factor)                                                                                                                           |
| **Protein Family**                  | PEA3 subfamily of ETS (E26 Transformation-Specific) transcription factors (with *ETV1* and *ETV5*)                                                                                      |
| **Normal Subcellular Localization** | **Nuclear**                                                                                                                                                                             |
| **Primary Pathological Mechanism**  | Transcriptional activation by chimeric **CIC fusion oncoproteins** (*CIC::DUX4*, *CIC::FOXO4*, *CIC::LEUTX*) driving massive upregulation of ETV4 mRNA and nuclear protein accumulation |
| **Primary Clinical Application**    | **Highly sensitive (>90–95%) surrogate immunohistochemical marker** for **CIC-rearranged round cell sarcomas**                                                                          |

***

## Pathophysiology: The Molecular Surrogate Mechanism

CIC-rearranged sarcomas represent an aggressive category of undifferentiated small round cell sarcomas of soft tissue and bone, predominantly affecting children and young adults (peak 2nd–3rd decades).

```
┌────────────────────────────────────────────────────────────────────────────────────────┐
│                        MOLECULAR SURROGATE MECHANISM OF ETV4                           │
└────────────────────────────────────────────────────────────────────────────────────────┘

  CHROMOSOMAL TRANSLOCATION:
    t(4;19)(q35;q13.1)  or  t(10;19)(q26.3;q13.1)
                            │
                            ▼
  CHIMERIC ONCOPROTEIN:
    [ CIC (transcriptional repressor) ] ──Fused with──► [ DUX4 (potent transactivator) ]
                            │
                            ▼ (Conversion from repressor to aberrant super-activator)
  DIRECT TARGET GENE OVEREXPRESSION:
    High-affinity binding to downstream ETS promoters:
    • ETV4 (massive upregulation: >100-fold)
    • ETV1 / ETV5
    • WT1 (Wilms tumor 1)
                            │
                            ▼
  IMMUNOHISTOCHEMICAL READOUT:
    [ Diffuse, Strong Nuclear ETV4 Staining (≥90–95% of tumor cells) ]
```

### Why ETV4 IHC Resolves the Molecular Testing Bottleneck

1. **The Subtelomeric DUX4 Problem:** In over 95% of CIC-rearranged sarcomas, the translocation partner is *DUX4*, located within the highly polymorphic, repetitive **D4Z4 macrosatellite repeat region** on subtelomeric 4q35 and 10q26.
2. **False Negatives in Standard Molecular Tests:**
   * Standard dual-color break-apart FISH probes often fail or give ambiguous signals due to repeat sequence cross-hybridization.
   * Targeted RNA-sequencing panels and anchored multiplex PCR (AMP) can suffer from read alignment dropouts or miss atypical fusion breakpoints.
3. **Clinical Utility:** Strong, diffuse nuclear ETV4 staining (especially when accompanied by nuclear WT1 co-positivity) provides rapid, reliable, and cost-effective confirmation of a CIC-rearranged sarcoma without awaiting complex multi-week molecular triage.

***

## Differential Diagnosis in Small Round Blue Cell Sarcomas

The differential diagnosis of small round cell tumors requires an integrated, multi-marker immunohistochemical panel:

| Entity                                          | Primary Genetic Alteration                              | ETV4 (Nuclear)         | WT1 (Nuclear)             | NKX2-2 (Nuclear)       | CD99 (Membranous)                  | BCOR (Nuclear)         | Other Defining Markers                                                        |
| ----------------------------------------------- | ------------------------------------------------------- | ---------------------- | ------------------------- | ---------------------- | ---------------------------------- | ---------------------- | ----------------------------------------------------------------------------- |
| **CIC-Rearranged Sarcoma**                      | `t(4;19)` / `t(10;19)` (*CIC::DUX4*)                    | **Strong Diffuse (+)** | **Positive (diffuse)**    | **Negative**           | Patchy / Weak / Variable           | Negative / Patchy      | Calretinin (+ in \~50%); Claudin-1 (+); occasional focal keratin              |
| **Ewing Sarcoma**                               | `t(11;22)` (*EWSR1::FLI1*) or `t(21;22)` (*EWSR1::ERG*) | **Negative**           | Negative                  | **Strong Diffuse (+)** | **Strong Diffuse Membranous (3+)** | Negative               | FLI1 (+), ERG (+), CAV1 (+)                                                   |
| **BCOR-Rearranged Sarcoma**                     | `t(X;p)` (*BCOR::CCNB3*), *ZC3H7B::BCOR*, *BCOR-ITD*    | **Negative**           | Negative                  | Negative               | Patchy / Membranous                | **Strong Diffuse (+)** | **CCNB3 (+ nuclear)**, SATB2 (+), Cyclin D1 (+)                               |
| **Poorly Differentiated Synovial Sarcoma**      | `t(X;18)` (*SS18::SSX1/2/4*)                            | **Negative**           | Negative                  | Negative               | Positive / Variable                | Negative               | **SS18-SSX (E9X9V +)**, **TLE1 (+ strong nuclear)**, Keratin / EMA (+ focal)  |
| **Desmoplastic Small Round Cell Tumor (DSRCT)** | `t(11;22)` (*EWSR1::WT1*)                               | **Negative**           | **Positive (C-terminus)** | Negative               | Variable                           | Negative               | **Polyphenotypic:** Cytokeratin (+), Desmin (+ dot-like paranuclear), NSE (+) |
| **Alveolar Rhabdomyosarcoma**                   | `t(2;13)` / `t(1;13)` (*PAX3/7::FOXO1*)                 | **Negative**           | Negative                  | Negative               | Negative / Patchy                  | Negative               | **Myogenin (+ diffuse)**, MyoD1 (+), Desmin (+)                               |

***

## Histomorphological Features of CIC-Reararranged Sarcoma

* **Architectural Patterns:** Multinodular or diffuse sheets of primitive cells separated by fibrous septa; prominent geographical necrosis is frequent.
* **Cytology:** Cells are round to ovoid with slightly more pleomorphism, vesicular chromatin, and prominent nucleoli than classical Ewing sarcoma. A clear cell or myxoid stromal background is seen in up to 30% of cases.
* **Rhabdoid or Epithelioid Change:** Tumors frequently display eccentrically displaced nuclei with glassy eosinophilic cytoplasm, mimicking malignant rhabdoid tumors or proximal-type epithelioid sarcomas.

***

## Secondary Expressions & Non-Sarcoma Contexts

While ETV4 is primarily deployed for round cell sarcomas:

1. **Gastrointestinal Stromal Tumors (GIST):** A subset of GISTs (particularly those that are *KIT* and *PDGFRA* wild-type or succinate dehydrogenase \[SDH]-deficient) show upregulation of ETV4 and other ETS factors.
2. **Prostatic Adenocarcinoma:** Rearrangements involving *ETV4* (such as *TMPRSS2::ETV4* or *SLC45A3::ETV4*) occur in 1–2% of prostate cancers, resulting in androgen-driven ETV4 nuclear overexpression.
3. **Salivary Secretory Carcinoma:** Rare cross-reactivity or transcriptional activation within the ETS family; however, *ETV6* break-apart FISH and pan-TRK / mammaglobin / S100 IHC remain the primary diagnostic standards.
4. **Endometrial / Ovarian Carcinoma:** High ETV4 mRNA/protein expression has been correlated with deep myometrial invasion, epithelial-mesenchymal transition (EMT), and unfavorable prognosis.

***

## Laboratory & Technical Specifications

| Parameter                      | Recommended Specification                                                                                                                                                                     |
| ------------------------------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **Representative Clones**      | **Polyclonal rabbit anti-ETV4** (e.g., Sigma-Aldrich HPA005768; Proteintech 10684-1-AP); **16F12** (mouse monoclonal); rabbit monoclonals validated per Hung et al. (*Am J Surg Pathol* 2016) |
| **Antigen Retrieval (HIER)**   | Heat-Induced Epitope Retrieval using **High pH buffer (Tris-EDTA, pH 9.0)** at 98–100°C for 20–30 min                                                                                         |
| **Optimal Staining Cutoff**    | **$\ge 20%$ strong nuclear staining** is considered positive; most true CIC-rearranged sarcomas exhibit **$>80–90%$ strong, diffuse nuclear positivity**                                      |
| **Positive Control Tissue**    | Normal adult human **testis** (spermatogonia / seminiferous tubules), appendix mucosa, or a verified CIC-rearranged index sarcoma FFPE block                                                  |
| **Negative Control Tissue**    | Lymphoid tissue (tonsil) or conventional Ewing sarcoma block                                                                                                                                  |
| **Quality Reporting Standard** | Document percentage of positive tumor nuclei, staining intensity (1+ to 3+), and recommend confirmatory *CIC* break-apart FISH or RNA sequencing if clinical or morphological doubt persists  |
